Tuesday, 28 June 2022

Adlai Nortye appoints Dr. Victoria Demby as Sr. VP of Global Regulatory Affairs

15 March 2022 | News

Dr Demby has over 20-year diverse industry experience

Adlai Nortye Ltd., a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, is pleased to welcome new senior level talent to its dynamic global leadership team. Victoria Demby will join the Company as Senior Vice President of Global Regulatory Affairs. Victoria will have responsibility for Adlai Nortye's global regulatory strategies across the portfolio as well as leading global regulatory submissions and interactions with regulatory bodies across geographies.

Dr. Demby has over 20-year diverse industry experience, most recently serving as Interim Vice President, Head Oncology Regulatory Therapeutic Group at GlaxoSmithKline, Inc. Prior to this, she was an Executive Director and Global Regulatory Lead at Merck where she successfully obtained global marketing application approvals for several Keytruda indications. Victoria is an experienced Regulatory Affairs professional holding regulatory roles of increasing responsibility at Bristol-Myers Squibb and Merck in various therapeutic areas including oncology, cardio-renal, metabolic, neurology and immunology.


Dr. Demby earned a bachelor degree in Biochemistry from University of Vermont and a doctoral degree in Pharmacology and Toxicology from University of Kansas.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account